London Daily

Focus on the big picture.
Saturday, Jul 19, 2025

Pfizer sees revenues double to $81bn thanks to COVID-19 vaccine

Pfizer sees revenues double to $81bn thanks to COVID-19 vaccine

The US drugs giant, which sold $37bn worth of the jab last year and expects sales of $32bn this year, said it had put "billions of dollars of capital on the line" in the early stages of the pandemic to develop the drug.

Drugs giant Pfizer has doubled annual sales and profits thanks to its COVID-19 vaccine.

The US firm said revenues rose from $41.7bn in 2020 to $81.3bn last year, largely thanks to the vaccine, known as Comirnaty - which accounted for $36.8bn of the total.

Profits climbed from $9.2bn to $22bn.

Pfizer's antiviral pill aims to reduce hospitalisation and deaths in high-risk patients


Pfizer said it expected sales of the vaccine - developed with Germany's BioNTech - to be worth $32bn this year, but that figure fell short of analysts' expectations for around $34bn.

It pencilled in a revenue figure of $22bn for COVID-19 oral antiviral treatment Paxlovid for 2022, which also fell a little short of Wall Street's target. Shares fell 3%.

Pfizer's vaccine is used in more than 160 countries.

It aims to make more than four billion doses in 2022, compared with last year's three billion.

Paxlovid has shown promise in cutting hospitalisation and deaths in high-risk patients and the company expects to produce at least 120 million courses of the pill this year.

Pfizer chief executive Albert Bourla said that in the early days of the COVID-19 pandemic, the company put "all of the resources and expertise we had at our disposal to help protect populations globally against this deadly virus as well as to offer treatments to help avoid the worst outcomes".

Albert Bourla said Pfizer's work had 'made a positive difference in the world'.


"We put billions of dollars of capital on the line in pursuit of those goals, not knowing whether those investments would ever pay off," Dr Bourla added.

He said that the successes of its COVID-19 treatments had "made a positive difference in the world".

Pfizer's results showed that it sold $7.8bn worth of its jab in the US, $9.4bn in western Europe and $8.1bn in other developed nations including Canada, Japan, South Korea, Australia and New Zealand.

Sales of Comirnaty to emerging markets - including the rest of Asia, Africa, the Middle East, Latin America and central and eastern Europe, totalled $11.4bn.

The amount of money being made by some drug companies from coronavirus jabs has proved controversial and campaigners have called for a waiver on vaccine patents, in order to allow cheap generic versions to be produced and distributed in poorer countries.

In December, World Health Organisation boss Tedros Adhanom Ghebreyesus warned that widespread COVID-19 vaccine booster programmes in developed countries were "likely to prolong the pandemic".

That was because, he said, they risked diverting supply to countries that had high levels of their populations already jabbed and away from those that need it most.

Anglo-Swedish drugs giant AstraZeneca, which reports full-year results later this week, has in contrast to rivals been selling its COVID-19 at cost.

But it was criticised when late last year it said it now planned to start making a "modest" profit from the drug.

Newsletter

Related Articles

0:00
0:00
Close
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
King Charles Meets David Beckham at Chelsea Flower Show
If the Department is Really About Justice: Ghislaine Maxwell Should Be Freed Now
NYC Candidate Zohran Mamdani’s ‘Antifada’ Remarks Spark National Debate on Political Language and Economic Policy
President Trump Visits Flood-Ravaged Texas, Praises Community Strength and First Responders
From Mystery to Meltdown, Crisis Within the Trump Administration: Epstein Files Ignite A Deepening Rift at the Highest Levels of Government Reveals Chaos, Leaks, and Growing MAGA Backlash
Trump Slams Putin Over War Death Toll, Teases Major Russia Announcement
Reparations argument crushed
Rainmaker CEO Says Cloud Seeding Paused Before Deadly Texas Floods
×